Benitec Says European Patent Forthcoming on HCV Inhibition Technology

The rights to the intellectual property were previously licensed to Tacere Therapeutics, which is developing an shRNA-based HCV therapy with Pfizer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories